Alzprotect is a biopharmaceutical company focused on developing drugs for the treatment of progressive supranuclear palsy (PSP) and Alzheimer's disease.
Parexel Biotech today announced that it has been selected to conduct the clinical Ph IIa development of AZP2006, Alzprotect’s flagship product.
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have granted AZP2006 orphan drug status in the indication of PSP.
AZP2006 was previously tested in two Phase I trials and demonstrated excellent tolerability, with no adverse effects, according to the company.
Parexel Biotech’s offering will include regulatory and strategic consulting, the ability to recruit patients and conduct trials, generation of real-world evidence (RWE) leveraging internal expertise and partnerships, such as with Datavant and SHYFT Analytics, among others.
The contract research organization (CRO) launched the dedicated biotech division earlier this year.
